HC Wainwright Has Bearish Estimate for JANX FY2029 Earnings

Key Points

• HC Wainwright has revised its earnings per share (EPS) estimate for Janux Therapeutics for FY2029 from $2.09 to $1.96, reflecting a more bearish outlook.
• Janux Therapeutics reported a quarterly EPS of ($0.55), which was below the consensus estimate of ($0.48), missing expectations by $0.07.
• The stock currently has an average rating of "Buy" with a consensus price target of $91.89, despite trading at $22.67, indicating substantial potential upside.

Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Investment analysts at HC Wainwright decreased their FY2029 earnings per share (EPS) estimates for Janux Therapeutics in a report released on Monday, August 11th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $1.96 for the year, down from their prior forecast of $2.09. The consensus estimate for Janux Therapeutics' current full-year earnings is ($1.38) per share.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.07).

Separately, Raymond James Financial began coverage on Janux Therapeutics in a report on Friday, July 11th. They issued an "outperform" rating and a $65.00 price objective on the stock. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Janux Therapeutics has a consensus rating of "Buy" and a consensus price target of $91.89.

Janux Therapeutics Stock Down 0.7%

Shares of JANX stock opened at $22.67 on Tuesday. The business has a 50-day moving average price of $24.65 and a two-hundred day moving average price of $28.72. Janux Therapeutics has a 12-month low of $21.97 and a 12-month high of $71.71. The firm has a market cap of $1.36 billion, a P/E ratio of -12.59 and a beta of 2.86.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of JANX. RA Capital Management L.P. boosted its position in Janux Therapeutics by 7.9% during the 1st quarter. RA Capital Management L.P. now owns 11,189,693 shares of the company's stock valued at $302,122,000 after acquiring an additional 824,041 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its position in Janux Therapeutics by 19.4% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,654,574 shares of the company's stock valued at $98,673,000 after acquiring an additional 592,824 shares in the last quarter. Janus Henderson Group PLC boosted its position in Janux Therapeutics by 41.2% during the 4th quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company's stock valued at $190,617,000 after acquiring an additional 1,038,996 shares in the last quarter. Paradigm Biocapital Advisors LP boosted its position in Janux Therapeutics by 46.5% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company's stock valued at $188,246,000 after acquiring an additional 1,115,412 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Janux Therapeutics by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 2,278,660 shares of the company's stock valued at $61,524,000 after acquiring an additional 142,328 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company's stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.